Enter your keyword

Efficiently Creating Value with Innovative Science

Press Releases

Date Title and Summary Additional Formats
Toggle Summary MATEON ANNOUNCES $2 MILLION FINANCING WITH GOLDEN MOUNTAIN PARTNERS TO CONDUCT CLINICAL TRIAL OF OT-101 AGAINST COVID19
AGOURA HILLS, Calif. , June 29, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (“Mateon” or the “Company”) (OTCQB:MATN) announces it has secured a $2 million in debt financing with Golden Mountain Partners (GMP) for the conduct of a clinical trial evaluating OT-101 against COVID-19.
View HTML
Toggle Summary Mateon is Selected by IBM Watson Health for the Use of IBM Clinical Development Solution at No Cost for Phase II Clinical Trial of OT-101 for COVID-19
Mateon was approved to use the platform following a review of the program as part of IBM Watson Health’s effort to help support and accelerate promising clinical COVID-19 candidates AGOURA HILLS, Calif. , June 24, 2020 (GLOBE NEWSWIRE) -- Oncotelic Inc. (“Oncotelic”), a wholly owned subsidiary of
View HTML
Toggle Summary Mateon Therapeutics Selects IQVIA for its Randomized, Controlled, Multi-Center Clinical Study to Test OT-101 as a Treatment for COVID-19 Patients
AGOURA HILLS, Calif. , June 23, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics (OTCQB: MATN), a leading developer of TGF-β therapeutics, has selected IQVIA to manage C001, a Phase 2 randomized, controlled, multi-center clinical study of OT-101. This study is designed to evaluate the safety,
View HTML
Toggle Summary Mateon and GMP Completed Research and Service Agreement
Mateon and GMP to proceed to clinical development of OT-101 and Artemisin and other antisense drug candidates against COVID-19 AGOURA HILLS, Calif. , June 22, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (“Mateon” or the “Company”)  (OTCQB:MATN) announces that both Golden Mountain Partners
View HTML
Toggle Summary Mateon Announces Achievement of Milestone Under Licensing of OT-101/IL-2 Combination to Autotelic BIO
The licensing agreement of OT-101 to Autotelic BIO with the field of use limited to OT-101 (Trabedersen) with Interleukin-2 (OT-101/IL-2) combination became effective this week with the completion of its first milestone and milestone payment by Autotelic BIO.
View HTML
Toggle Summary Mateon Announces an Expansion to its Pharmaceutical Manufacturing AI Camera Grid by Including Contact Tracing to Ensure Worker Safety
TracePoint vision grid will identify workers who came in contact with a sick coworker and alert operational staff. Mateon’s patented AI camera grid system is similar to Amazon’s technology but at a fraction of the cost. TracePoint will deploy a Fever Camera System to continuously monitor for
View HTML
Toggle Summary Mateon Provides Update on OT-101
AGOURA HILLS, Calif. , June 01, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics Inc.  (OTCQB:MATN) report several peer-reviewed publications derived from its R&D effort against COVID-19. Fatih M. Uckun , Vuong Trieu .  Targeting Transforming Growth Factor-beta for Treatment of COVID-19-associated
View HTML
Toggle Summary FDA Grants Pediatric Disease Designation for Mateon’s CA4P
Treatment of stage IIB–IV melanoma due to genetic mutations that disproportionately affect pediatric patients AGOURA HILLS, Calif. , May 05, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics Inc. (OTCQB:MATN) announced today that the US Food and Drug Administration (FDA) granted Rare Pediatric Disease
View HTML
Toggle Summary Mateon Provides Update on its R&D Effort Against COVID-19
AGOURA HILLS, Calif. , April 30, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics Inc. (OTCQB:MATN) report several peer-reviewed publications derived from its R&D effort against COVID-19. Published April 24 th , is a special report in the biomedical journal Annals of Pulmonary and Critical Care
View HTML
Toggle Summary Mateon Announces the Filing of an IND with US FDA to Evaluate its Antisense Drug Candidate OT-101 in COVID-19 patients
AGOURA HILLS, Calif. , April 27, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics Inc. (OTCQB:MATN) announced today it has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) to study its investigational drug, OT-101, for the treatment of COVID-19
View HTML